Group 1 - The core viewpoint of the article highlights the significant stock price surge of Baize Medical (2609.HK), which rose over 50% in one day and further increased by 94% to reach HKD 19.88, marking a total increase of 192% over two days, with a market capitalization exceeding HKD 26 billion [1] - Baize Medical is primarily engaged in investment and provision of medical services related to oncology, operating six proprietary for-profit hospitals and managing two non-profit hospitals across various regions including Beijing, Tianjin, and Anhui [1] - The company’s flagship hospital is Beijing Xiyuan Cancer Hospital, which offers core services such as cancer screening, diagnosis, treatment, and rehabilitation [1] Group 2 - The inclusion of Baize Medical in the Hong Kong Stock Connect program, effective from September 8, has contributed to its stock price surge [1]
港股异动丨佰泽医疗连续两日飙升，累涨192%